-+ 0.00%
-+ 0.00%
-+ 0.00%

Palvella Reports QTORIN Rapamycin Improves Disease Severity in Children in Phase 3 SELVA Study

PUBT·10/15/2026 11:33:32
Listen to the news
Palvella Reports QTORIN Rapamycin Improves Disease Severity in Children in Phase 3 SELVA Study
  • Palvella Therapeutics will present previously reported QTORIN rapamycin trial results with new pediatric analyses at PeDRA on Oct. 15, 2026.
  • Phase 3 SELVA pediatric analyses showed improved overall disease severity and lesion characteristics in children with microcystic lymphatic malformations.
  • Phase 2 TOIVA pediatric analyses showed reduced disease severity and lesion bleeding in previously treated children with cutaneous venous malformations.
  • QTORIN rapamycin remains investigational; neither condition has an FDA-approved therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150730PRIMZONEFULLFEED9846272) on October 15, 2026, and is solely responsible for the information contained therein.